New Delhi: Drug Controller General Of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Virafin is a pegylated interferon alpha-2b(PegIFN), which when s
DCGI gives EUA to Zydus for using Virafin on COVID-19 patients
DCGI gives EUA to Zydus for using Virafin on COVID-19 patients
23 April 2021 | News A single dose of the antiviral Virafin administered subcutaneously early on shows
significant clinical and virological improvement in moderate COVID-19 adult patients
Image credit- shutterstock.com
Zydus Cadila ha announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
3 46 Lakh Fresh COVID-19 Cases In India, 2,624 Deaths In New Record High ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
Zydus Virafin gets emergency use approval for treating moderate COVID-19 cases ANI | Updated: Apr 23, 2021 16:04 IST
New Delhi [India], April 23 (ANI): The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila s Pegylated Interferon alpha-2b, Virafin for treating moderate COVID-19 infection in adults.
A release by Cadila Health said, The drug has also shown efficacy against other viral infections.
Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said: The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.